BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249-77. [PMID: 18215115 DOI: 10.1146/annurev.pathmechdis.3.121806.154311] [Cited by in Crossref: 139] [Cited by in F6Publishing: 106] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
2 Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. British Journal of Haematology 2008;143:336-48. [DOI: 10.1111/j.1365-2141.2008.07324.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
3 Keir LS. Shiga Toxin Associated Hemolytic Uremic Syndrome. Hematology/Oncology Clinics of North America 2015;29:525-39. [DOI: 10.1016/j.hoc.2015.01.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
4 Veyradier A, Coppo P. ADAMTS13, la protéase spécifique du clivage du facteur von Willebrand. Med Sci (Paris) 2011;27:1097-105. [DOI: 10.1051/medsci/20112712016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
5 Legros N, Dusny S, Humpf HU, Pohlentz G, Karch H, Müthing J. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells. Glycobiology 2017;27:99-109. [PMID: 27558838 DOI: 10.1093/glycob/cww090] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
6 Minami SB, Takegoshi H, Shinjo Y, Kaga K. Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children. J Laryngol Otol 2013;127:306-10. [PMID: 23406716 DOI: 10.1017/S0022215113000145] [Reference Citation Analysis]
7 Legros N, Pohlentz G, Steil D, Müthing J. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells. Int J Med Microbiol 2018;308:1073-84. [PMID: 30224239 DOI: 10.1016/j.ijmm.2018.09.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
8 Mariani M, Cairo A, Palla R, Lotta LA, Consonni D, Rovati A, Trisolini S, Peyvandi F. B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thrombosis Research 2011;128:590-2. [DOI: 10.1016/j.thromres.2011.07.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Zheng L, Abdelgawwad MS, Zhang D, Xu L, Wei S, Cao W, Zheng XL. Histone-induced thrombotic thrombocytopenic purpura in adamts13 -/- zebrafish depends on von Willebrand factor. Haematologica 2020;105:1107-19. [PMID: 31753928 DOI: 10.3324/haematol.2019.237396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sane DC, Streer NP, Owen J. Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. European Journal of Haematology 2009;82:83-92. [DOI: 10.1111/j.1600-0609.2008.01172.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
11 Briones MA. Hemolytic Uremic Syndrome. Transfusion Medicine and Hemostasis. Elsevier; 2013. pp. 669-74. [DOI: 10.1016/b978-0-12-397164-7.00102-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Bao J, Xiao J, Mao Y, Zheng XL. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. Arterioscler Thromb Vasc Biol 2014;34:397-407. [PMID: 24357063 DOI: 10.1161/ATVBAHA.113.302547] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
13 Rank CU, Kremer Hovinga J, Taleghani MM, Lämmle B, Gøtze JP, Nielsen OJ. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene. Eur J Haematol 2014;92:168-71. [DOI: 10.1111/ejh.12197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
14 Hanby HA, Zheng XL. Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura. Hereditary Genet 2014;3:e108. [PMID: 25343060 DOI: 10.4172/2161-1041.1000e108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012;120:1157-64. [PMID: 22611154 DOI: 10.1182/blood-2012-02-412197] [Cited by in Crossref: 162] [Cited by in F6Publishing: 158] [Article Influence: 16.2] [Reference Citation Analysis]
16 Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014;29:1895-902. [PMID: 23843163 DOI: 10.1007/s00467-013-2561-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
17 Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 2011;26:523-33. [PMID: 20949284 DOI: 10.1007/s00467-010-1637-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
18 Pillai VG, Bao J, Zander CB, McDaniel JK, Chetty PS, Seeholzer SH, Bdeir K, Cines DB, Zheng XL. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood 2016;128:110-9. [PMID: 27207796 DOI: 10.1182/blood-2015-12-688747] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
19 Feys HB, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, van Rensburg WJ, Anderson PJ, Budde U, Louw VJ, Badenhorst PN, Deckmyn H, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010;116:2005-10. [DOI: 10.1182/blood-2010-04-280479] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
20 Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJH, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. The Journal of Maternal-Fetal & Neonatal Medicine 2012;25:2322-5. [DOI: 10.3109/14767058.2012.694923] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zheng L, Mao Y, Abdelgawwad MS, Kocher NK, Li M, Dai X, Li B, Zheng XL. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv 2016;1:75-83. [PMID: 28480350 DOI: 10.1182/bloodadvances.2016000711] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
22 Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010;115:1640-9. [PMID: 20032502 DOI: 10.1182/blood-2009-06-229203] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 7.0] [Reference Citation Analysis]
23 Lesher AM, Song WC. Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010;15:663-75. [PMID: 21040161 DOI: 10.1111/j.1440-1797.2010.01373.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
24 Batsford S, Duermueller U, Seemayer C, Mueller C, Hopfer H, Mihatsch M. Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease. Nephrol Dial Transplant 2011;26:1413-6. [PMID: 21220755 DOI: 10.1093/ndt/gfq752] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
25 Liu Y, Zhu J, Xi EP, Jiang W, Xia F, Zhu SB. Successful treatment of thrombotic thrombocytopenic purpura associated with mitral valve replacement. Clinics (Sao Paulo) 2012;67:1527-8. [PMID: 23295615 DOI: 10.6061/clinics/2012(12)31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Kemper C, Atkinson JP. Measles virus and CD46. Curr Top Microbiol Immunol 2009;329:31-57. [PMID: 19198561 DOI: 10.1007/978-3-540-70523-9_3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
27 Yin H, Stojanovic-Terpo A, Xu W, Corken A, Zakharov A, Qian F, Pavlovic S, Krbanjevic A, Lyubimov AV, Wang ZJ, Ware J, Du X. Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol 2013;33:2529-37. [PMID: 24051142 DOI: 10.1161/ATVBAHA.113.302339] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
28 Jin SY, Xiao J, Bao J, Zhou S, Wright JF, Zheng XL. AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood 2013;121:3825-9, S1-3. [PMID: 23515928 DOI: 10.1182/blood-2013-02-486779] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
29 Xing J, Wang H, Brookes PC, Salles JF, Xu J. Soil pH and microbial diversity constrain the survival of E. coli in soil. Soil Biology and Biochemistry 2019;128:139-49. [DOI: 10.1016/j.soilbio.2018.10.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
30 Hermann R, Pfeil A, Busch M, Kettner C, Kretzschmar D, Hansch A, La Rosée P, Wolf G. [Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination]. Med Klin (Munich) 2010;105:663-8. [PMID: 20878304 DOI: 10.1007/s00063-010-1107-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wang Y, Chen J, Ling M, López JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem 2015;290:1422-31. [PMID: 25422322 DOI: 10.1074/jbc.M114.599084] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
32 Hildebrand AM, Huang SS, Clark WF. Plasma Exchange for Kidney Disease: What Is the Best Evidence? Advances in Chronic Kidney Disease 2014;21:217-27. [DOI: 10.1053/j.ackd.2014.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
33 Hellmann M, Hallek M, Scharrer I. [Thrombotic-thrombocytopenic purpura]. Internist (Berl) 2010;51:1136, 1138-44. [PMID: 20689903 DOI: 10.1007/s00108-010-2599-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Abdelgawwad MS, Cao W, Zheng L, Kocher NK, Williams LA, Zheng XL. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura. Arterioscler Thromb Vasc Biol 2018;38:2731-43. [PMID: 30354235 DOI: 10.1161/ATVBAHA.118.311407] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
35 Samia NI, Friedman KD, Gottschall JL, Raife TJ. Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy. J Clin Apher 2011;26:138-45. [PMID: 21462238 DOI: 10.1002/jca.20284] [Reference Citation Analysis]
36 Li R. The Glycoprotein Ib-IX-V Complex. Platelets. Elsevier; 2019. pp. 193-211. [DOI: 10.1016/b978-0-12-813456-6.00010-2] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Orvain C, Augusto JF, Besson V, Marc G, Coppo P, Subra JF, Sayegh J. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 2014;46:239-42. [PMID: 23435773 DOI: 10.1007/s11255-013-0401-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
38 Gnudi L, Benedetti S, Woolf AS, Long DA. Vascular growth factors play critical roles in kidney glomeruli. Clin Sci (Lond) 2015;129:1225-36. [PMID: 26561594 DOI: 10.1042/CS20150403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
39 Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 2011;4:51-9. [PMID: 21727765 DOI: 10.5144/1658-3876.2011.51] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
40 Eremina V, Quaggin SE. Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy. Seminars in Nephrology 2010;30:582-90. [DOI: 10.1016/j.semnephrol.2010.09.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
41 Han Y, Xiao J, Falls E, Zheng XL. A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion 2011;51:1580-91. [PMID: 21251003 DOI: 10.1111/j.1537-2995.2010.03020.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
42 Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008;6:1233-1235. [PMID: 18433458 DOI: 10.1111/j.1538-7836.2008.02989.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
43 Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost. 2013;11 Suppl 1:11-23. [PMID: 23809107 DOI: 10.1111/jth.12221] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
44 Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol 2009;24:19-29. [PMID: 18574602 DOI: 10.1007/s00467-008-0863-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
45 Song D, Yu X, Wang F, Xu B, He Y, Chen Q, Wang S, Yu F, Song W, Zhao M. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement. Am J Reprod Immunol 2015;74:345-56. [DOI: 10.1111/aji.12404] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
46 Maginnis P, Anderton J, Nair B, Woywodt A. tHe USual Suspects. NDT Plus 2011;4:260-3. [PMID: 25949498 DOI: 10.1093/ndtplus/sfr031] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis 2018;29:243-51. [PMID: 29517503 DOI: 10.1097/MBC.0000000000000720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
48 Jian C, Xiao J, Gong L, Skipwith CG, Jin SY, Kwaan HC, Zheng XL. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012;119:3836-43. [PMID: 22289888 DOI: 10.1182/blood-2011-12-399501] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
49 Erzurumluoglu AM, Rodriguez S, Shihab HA, Baird D, Richardson TG, Day IN, Gaunt TR. Identifying Highly Penetrant Disease Causal Mutations Using Next Generation Sequencing: Guide to Whole Process. Biomed Res Int 2015;2015:923491. [PMID: 26106619 DOI: 10.1155/2015/923491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
50 Liu AR, Hildebrand AM, Dixon S, Sontrop JM, Clark WF, Lazo-Langner A, Nash D, Garg AX. A matched case-control study to assess the association between non-steroidal anti-inflammatory drug use and thrombotic microangiopathy. PLoS One 2018;13:e0202801. [PMID: 30142223 DOI: 10.1371/journal.pone.0202801] [Reference Citation Analysis]
51 Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020;11:577027. [PMID: 33391257 DOI: 10.3389/fimmu.2020.577027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
52 Sui J, Lu R, Halkidis K, Kocher NK, Cao W, Marques MB, Zheng XL. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. J Thromb Haemost 2021;19:370-9. [PMID: 33188723 DOI: 10.1111/jth.15176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Yadav S, Shetty S, Kulkarni B. A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report. Transfusion 2017;57:2712-4. [PMID: 28833243 DOI: 10.1111/trf.14279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
54 Pos W, Luken BM, Sorvillo N, Kremer Hovinga JA, Voorberg J. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2011;9:1285-91. [PMID: 21535387 DOI: 10.1111/j.1538-7836.2011.04307.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
55 Park YA, Poisson JL, Mcbee MT, Afenyi-annan A. Seasonal association of thrombotic thrombocytopenic purpura: SEASONAL OCCURRENCE OF TTP. Transfusion 2012;52:1530-4. [DOI: 10.1111/j.1537-2995.2011.03481.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ormonde C, Querido S, Rombo N, Roque R, Clemente B, Weigert A. Primary Hyperaldosteronism: A Rare Cause of Malignant Hypertension with Thrombotic Microangiopathy in a Kidney Transplant Recipient. Case Rep Transplant 2021;2021:9261371. [PMID: 34820145 DOI: 10.1155/2021/9261371] [Reference Citation Analysis]
57 Hanby HA, Zheng XL. Biochemistry and physiological functions of ADAMTS7 metalloprotease. Adv Biochem 2013;1. [PMID: 24222922 DOI: 10.11648/j.ab.20130103.11] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
58 Schmidt T, Tsakiris DA, Grapow M, Siegemund M. [Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis]. Anaesthesist 2011;60:451-6. [PMID: 21184040 DOI: 10.1007/s00101-010-1819-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Tsimpanakos I, Connolly J, Alatzoglou KS, Rowan C, Magos A. Two cases of myomectomy complicated by intravascular hemolysis and renal failure: disseminated intravascular coagulation or hemolytic uremic syndrome? Fertil Steril 2010;93:2075.e11-5. [PMID: 20056203 DOI: 10.1016/j.fertnstert.2009.11.023] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
60 Elghetany MT, Banki K. Erythrocytic Disorders. Henry's Clinical Diagnosis and Management by Laboratory Methods. Elsevier; 2011. pp. 557-600. [DOI: 10.1016/b978-1-4377-0974-2.00032-4] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
61 Banno F, Chauhan AK, Kokame K, Yang J, Miyata S, Wagner DD, Miyata T. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 2009;113:5323-9. [PMID: 19109562 DOI: 10.1182/blood-2008-07-169359] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
62 George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060-9. [PMID: 20686117 DOI: 10.1182/blood-2010-07-271445] [Cited by in Crossref: 301] [Cited by in F6Publishing: 240] [Article Influence: 25.1] [Reference Citation Analysis]
63 Milošević B, Stojanović V, Nikolić M, Konstantinidis G, Rudić A. Common variable immunodeficiency complicated with hemolytic uremic syndrome. Ups J Med Sci 2012;117:67-71. [PMID: 22059898 DOI: 10.3109/03009734.2011.635815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Mutneja A, Cossey LN, Liapis H, Chen YM. A rare case of renal thrombotic microangiopathy associated with Castleman's disease. BMC Nephrol 2017;18:57. [PMID: 28183278 DOI: 10.1186/s12882-017-0472-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012;6:195-208. [PMID: 22888220 DOI: 10.2147/DDDT.S25757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
66 Moatti-cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012;119:5888-97. [DOI: 10.1182/blood-2012-02-408914] [Cited by in Crossref: 144] [Cited by in F6Publishing: 114] [Article Influence: 14.4] [Reference Citation Analysis]
67 Mai Falk J, Scharrer I. Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse. Transfusion 2016;56:2819-23. [PMID: 27514869 DOI: 10.1111/trf.13751] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
68 Ortel TL, Kitchens CS, Erkan D, Brandão LR, Hahn S, James AH, Kulkarni R, Manco-Johnson MJ, Pericak-Vance M, Vance J. Clinical causes and treatment of the thrombotic storm. Expert Rev Hematol 2012;5:653-9. [PMID: 23216595 DOI: 10.1586/ehm.12.56] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
69 Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010;56:1168-74. [PMID: 20843591 DOI: 10.1053/j.ajkd.2010.06.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
70 Zheng XL. ADAMTS13 testing: why bother? Blood 2010;115:1475-6. [DOI: 10.1182/blood-2010-01-262709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
71 Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010;285:28596-603. [PMID: 20605782 DOI: 10.1074/jbc.M110.131227] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
72 Bao J, Mo B, An G, Luo J, Poncz M, Pan G, Li T, Zhou Z. Von Willebrand Factor Facilitates Intravascular Dissemination of Microsporidia Encephalitozoon hellem. Front Cell Infect Microbiol 2021;11:694957. [PMID: 34095003 DOI: 10.3389/fcimb.2021.694957] [Reference Citation Analysis]
73 Stepanian A, Cohen-Moatti M, Sanglier T, Legendre P, Ameziane N, Tsatsaris V, Mandelbrot L, de Prost D, Veyradier A. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol. 2011;31:1703-1709. [PMID: 21512165 DOI: 10.1161/atvbaha.111.223610] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
74 Detzner J, Pohlentz G, Müthing J. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2020;12:E373. [PMID: 32512916 DOI: 10.3390/toxins12060373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Pipili C, Pantelias K, Papaioannou N, Paraskevakou H, Grapsa E. Hemolytic-uremic syndrome, malignant hypertension and IgA nephropathy: successful treatment with plasma exchange therapy. Transfus Apher Sci 2012;47:155-8. [PMID: 22892290 DOI: 10.1016/j.transci.2012.06.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
76 Marks PW. Coagulation disorders in the ICU. Clin Chest Med 2009;30:123-9, ix. [PMID: 19186284 DOI: 10.1016/j.ccm.2008.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
77 Rossi FC, Angerami RN, de Paula EV, Orsi FL, Shang D, del Guercio VM, Resende MR, Annichino-Bizzacchi JM, da Silva LJ, Zheng XL, Castro V. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion 2010;50:208-12. [PMID: 19788513 DOI: 10.1111/j.1537-2995.2009.02391.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
78 Kopić A, Benamara K, Piskernik C, Plaimauer B, Horling F, Höbarth G, Ruthsatz T, Dietrich B, Muchitsch EM, Scheiflinger F, Turecek M, Höllriegl W. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 2016;14:1410-9. [PMID: 27371116 DOI: 10.1111/jth.13341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
79 Benevides TCL, Orsi FA, Colella MP, Percout PDO, Moura MS, Dias MA, Lins BD, Paula EVD, Vassallo J, Annichino-bizzachi J. Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman’s disease: A case report. Platelets 2014;26:263-6. [DOI: 10.3109/09537104.2014.904504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Johnson RJ, Nangaku M. Endothelial Dysfunction: The Secret Agent Driving Kidney Disease. J Am Soc Nephrol 2016;27:3-5. [PMID: 26038532 DOI: 10.1681/ASN.2015050502] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.1] [Reference Citation Analysis]
81 Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357. [PMID: 19625716 DOI: 10.1056/nejmoa0810739] [Cited by in Crossref: 368] [Cited by in F6Publishing: 153] [Article Influence: 28.3] [Reference Citation Analysis]
82 Shome DK, Ramadorai P, Al-ajmi A, Ali F, Malik N. Thrombotic microangiopathy in sickle cell disease crisis. Ann Hematol 2013;92:509-15. [DOI: 10.1007/s00277-012-1647-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
83 Wang CP, Young G, Thornburg CD. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opin Drug Saf 2021;20:387-96. [PMID: 33612049 DOI: 10.1080/14740338.2021.1893303] [Reference Citation Analysis]
84 Herisson F, Zhou I, Mawet J, Du E, Barfejani AH, Qin T, Cipolla MJ, Sun PZ, Rost NS, Ayata C. Posterior reversible encephalopathy syndrome in stroke-prone spontaneously hypertensive rats on high-salt diet. J Cereb Blood Flow Metab 2019;39:1232-46. [PMID: 29350576 DOI: 10.1177/0271678X17752795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
85 Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009;114:4538-45. [PMID: 19704120 DOI: 10.1182/blood-2009-03-205096] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
86 Pandey Y, Atwal D, Sasapu A. Diarrhea-associated Hemolytic Uremic Syndrome in Adults: Two Case Reports and Review of the Literature. Cureus 2019;11:e4435. [PMID: 31245222 DOI: 10.7759/cureus.4435] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther 2014;15:975-81. [PMID: 24842548 DOI: 10.4161/cbt.29187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
88 Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011;17:5858-66. [PMID: 21813634 DOI: 10.1158/1078-0432.CCR-11-0804] [Cited by in Crossref: 62] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
89 Taleghani M, von Krogh A, Fujimura Y, George JN, Hrachovinova I, Knöbl PN, Quist-paulsen P, Schneppenheim R, Lämmle B, Hovinga JA. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie 2018;33:138-43. [DOI: 10.5482/hamo-13-04-0026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 6.8] [Reference Citation Analysis]
90 Sorvillo N, Pos W, van den Berg LM, Fijnheer R, Martinez-Pomares L, Geijtenbeek TB, Herczenik E, Voorberg J. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 2012;119:3828-35. [PMID: 22289891 DOI: 10.1182/blood-2011-09-377754] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
91 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
92 Li X, Sim MMS, Wood JP. Recent Insights Into the Regulation of Coagulation and Thrombosis. Arterioscler Thromb Vasc Biol 2020;40:e119-25. [PMID: 32320291 DOI: 10.1161/ATVBAHA.120.312674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Memon R, Sui J, Lin C, Zheng XL. Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality. TH Open 2021;5:e1-7. [PMID: 33458563 DOI: 10.1055/s-0040-1722610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13 Suppl 1:S121-32. [PMID: 26149013 DOI: 10.1111/jth.12950] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
95 Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol 2011;31:2261-9. [PMID: 21799176 DOI: 10.1161/ATVBAHA.111.229609] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
96 Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 2010;115:2300-10. [PMID: 20075158 DOI: 10.1182/blood-2009-07-235101] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
97 Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19:1864-71. [PMID: 34060225 DOI: 10.1111/jth.15406] [Reference Citation Analysis]
98 Thouzeau S, Capdenat S, Stepanian A, Coppo P, Veyradier A. Evaluation of a commercial assay for ADAMTS13 activity measurement. Thromb Haemost 2017;110:852-3. [DOI: 10.1160/th13-05-0393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
99 Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost 2017;15:1889-900. [PMID: 28662310 DOI: 10.1111/jth.13764] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
100 Robertson JJ, Brem E, Koyfman A. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. The Journal of Emergency Medicine 2017;53:202-11. [DOI: 10.1016/j.jemermed.2017.02.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Feys HB, Pareyn I, Vancraenenbroeck R, De Maeyer M, Deckmyn H, Van Geet C, Vanhoorelbeke K. Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura. Blood 2009;114:4749-52. [PMID: 19786614 DOI: 10.1182/blood-2009-07-230615] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
102 Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010;95:1555-62. [PMID: 20378566 DOI: 10.3324/haematol.2009.019299] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 6.6] [Reference Citation Analysis]
103 Manea M, Karpman D. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol 2009;24:447-58. [DOI: 10.1007/s00467-008-0986-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
104 Thejeel B, Garg AX, Clark WF, Liu AR, Iansavichus AV, Hildebrand AM. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review: Outcomes of Thrombotic Microangiopathy. Am J Hematol 2016;91:623-30. [DOI: 10.1002/ajh.24339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
105 Cao W, Sabatino DE, Altynova E, Lange AM, Casina VC, Camire RM, Zheng XL. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease. J Biol Chem 2012;287:32459-66. [PMID: 22854959 DOI: 10.1074/jbc.M112.390690] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
106 Cao W, Abdelgawwad MS, Li J, Zheng XL. Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear. Thromb Haemost 2019;119:1933-46. [PMID: 31493779 DOI: 10.1055/s-0039-1696713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus Apher Sci 2016;54:203-11. [PMID: 27156109 DOI: 10.1016/j.transci.2016.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
108 Kumar MA, Cao W, Pham HP, Raju D, Nawalinski K, Maloney-Wilensky E, Schuster J, Zheng XL. Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury. J Neurotrauma 2019;36:222-9. [PMID: 29848170 DOI: 10.1089/neu.2018.5696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
109 Halkidis K, Siegel DL, Zheng XL. A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura. J Thromb Haemost 2021;19:1888-95. [PMID: 33834592 DOI: 10.1111/jth.15332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989–2007). Kidney International 2009;75:S8-S10. [DOI: 10.1038/ki.2008.609] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
111 Prinz WA, Hinshaw JE. Membrane-bending proteins. Critical Reviews in Biochemistry and Molecular Biology 2009;44:278-91. [DOI: 10.1080/10409230903183472] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]